SG11201906436VA - Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same - Google Patents
Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the sameInfo
- Publication number
- SG11201906436VA SG11201906436VA SG11201906436VA SG11201906436VA SG11201906436VA SG 11201906436V A SG11201906436V A SG 11201906436VA SG 11201906436V A SG11201906436V A SG 11201906436VA SG 11201906436V A SG11201906436V A SG 11201906436VA SG 11201906436V A SG11201906436V A SG 11201906436VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gyeonggi
- gil
- same
- heterocyclic compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170016971 | 2017-02-07 | ||
| PCT/KR2018/001625 WO2018147626A1 (fr) | 2017-02-07 | 2018-02-07 | Nouveau composé hétérocyclique, son procédé de préparation et composition pharmaceutique le comprenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906436VA true SG11201906436VA (en) | 2019-08-27 |
Family
ID=63107680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906436VA SG11201906436VA (en) | 2017-02-07 | 2018-02-07 | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10981917B2 (fr) |
| EP (1) | EP3580208B1 (fr) |
| JP (1) | JP6785384B2 (fr) |
| KR (1) | KR102084772B1 (fr) |
| CN (1) | CN110191882B (fr) |
| AR (1) | AR110963A1 (fr) |
| AU (1) | AU2018218965B2 (fr) |
| BR (1) | BR112019016291A2 (fr) |
| CA (1) | CA3049643C (fr) |
| CL (1) | CL2019002019A1 (fr) |
| CO (1) | CO2019007834A2 (fr) |
| DO (1) | DOP2019000193A (fr) |
| EC (1) | ECSP19051409A (fr) |
| ES (1) | ES2899665T3 (fr) |
| HR (1) | HRP20211483T1 (fr) |
| HU (1) | HUE056218T2 (fr) |
| MA (1) | MA47469B1 (fr) |
| MX (1) | MX2019009185A (fr) |
| MY (1) | MY196538A (fr) |
| PE (1) | PE20191477A1 (fr) |
| PH (1) | PH12019501811A1 (fr) |
| PL (1) | PL3580208T3 (fr) |
| PT (1) | PT3580208T (fr) |
| RS (1) | RS62541B1 (fr) |
| RU (1) | RU2733384C1 (fr) |
| SA (1) | SA519402180B1 (fr) |
| SG (1) | SG11201906436VA (fr) |
| SI (1) | SI3580208T1 (fr) |
| TN (1) | TN2019000204A1 (fr) |
| TW (4) | TWI700280B (fr) |
| WO (1) | WO2018147626A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018269947B2 (en) * | 2017-05-15 | 2021-10-14 | The Regents Of The University Of Michigan | Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors |
| KR102346187B1 (ko) * | 2019-12-26 | 2021-12-31 | 울산과학기술원 | 디히드로퓨란 유도체 및 이의 합성 방법 |
| EP4338733A1 (fr) | 2021-05-13 | 2024-03-20 | Daewoong Pharmaceutical Co., Ltd. | Composition pharmaceutique destinée à la prévention ou au traitement de la fibrose |
| WO2022240036A1 (fr) | 2021-05-13 | 2022-11-17 | 주식회사 대웅제약 | Composition pharmaceutique pour la prévention ou le traitement de la fibrose |
| KR20230015858A (ko) | 2021-07-23 | 2023-01-31 | 주식회사 대웅제약 | 전신경화증의 예방 또는 치료용 약학적 조성물 |
| WO2023055124A1 (fr) * | 2021-10-01 | 2023-04-06 | 주식회사유한양행 | Dérivé à noyau condensé bicyclique ou sel de celui-ci et composition pharmaceutique le comprenant |
| KR20230092630A (ko) * | 2021-12-17 | 2023-06-26 | 주식회사 대웅제약 | (2R, 3S)-2-(벤조[d]이미다졸일프로필)피페리딘-3-올 유도체의 제조 방법 |
| TW202334112A (zh) * | 2021-12-17 | 2023-09-01 | 南韓商大熊製藥股份有限公司 | (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形 |
| KR20230168984A (ko) * | 2022-06-08 | 2023-12-15 | 주식회사 대웅제약 | 아르기나아제 저해제 및 이를 포함하는 약학적 조성물 |
| WO2024080777A1 (fr) * | 2022-10-12 | 2024-04-18 | 주식회사 대웅제약 | Composition pharmaceutique pour la prévention ou le traitement de la néphrite |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8900719D0 (en) | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| DK0709384T3 (da) * | 1994-10-31 | 1999-08-23 | Merck Patent Gmbh | Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder |
| IL114951A (en) | 1995-08-15 | 1999-08-17 | Hadasit Med Res Service | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization |
| WO1997034895A1 (fr) | 1996-03-15 | 1997-09-25 | Novartis Ag | NOUVELLES N-7-HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINES ET LEUR UTILISATION |
| AU5500399A (en) * | 1999-08-20 | 2001-04-10 | Csl Silicones Inc. | One-part organopolysiloxane rubber composition for use as a corrosion protection coating |
| US20040147573A1 (en) | 2001-03-15 | 2004-07-29 | Anders Eriksson | Metalloproteinase inhibitors |
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| JP5833804B2 (ja) | 2005-04-13 | 2015-12-16 | ニューラクソン，インコーポレーテッド | Ｎｏｓ阻害活性を有する置換インドール化合物 |
| EP1939199A4 (fr) * | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | Nouveau compose d'adenine |
| CL2008000496A1 (es) | 2007-02-19 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias. |
| SG193149A1 (en) * | 2008-08-11 | 2013-09-30 | Glaxosmithkline Llc | Novel adenine derivatives |
| CN102177152A (zh) * | 2008-08-11 | 2011-09-07 | 哈佛大学校长及研究员协会 | 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途 |
| US20130338201A1 (en) | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| EP2830628A4 (fr) | 2012-03-29 | 2016-05-25 | Halo Therapeutics Llc | Formes galéniques d'halofuginone et méthodes d'utilisation |
| WO2014145576A2 (fr) * | 2013-03-15 | 2014-09-18 | Northwestern University | Pyrrolo(2,3-d)pyrimidines substituées pour le traitement du cancer |
| CA2951798C (fr) | 2014-06-23 | 2018-07-24 | Daewoong Pharmaceutical Co., Ltd. | Derives de febrifugine et leur utilisation comme inhibiteurs de la prolyl-trna synthetase (prs) |
| KR102277538B1 (ko) | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
-
2018
- 2018-02-06 AR ARP180100277A patent/AR110963A1/es unknown
- 2018-02-07 AU AU2018218965A patent/AU2018218965B2/en active Active
- 2018-02-07 RS RS20211375A patent/RS62541B1/sr unknown
- 2018-02-07 SI SI201830416T patent/SI3580208T1/sl unknown
- 2018-02-07 KR KR1020180015091A patent/KR102084772B1/ko active IP Right Grant
- 2018-02-07 MY MYPI2019004122A patent/MY196538A/en unknown
- 2018-02-07 MX MX2019009185A patent/MX2019009185A/es unknown
- 2018-02-07 CA CA3049643A patent/CA3049643C/fr active Active
- 2018-02-07 TN TNP/2019/000204A patent/TN2019000204A1/en unknown
- 2018-02-07 BR BR112019016291A patent/BR112019016291A2/pt active Search and Examination
- 2018-02-07 HR HRP20211483TT patent/HRP20211483T1/hr unknown
- 2018-02-07 TW TW108107266A patent/TWI700280B/zh active
- 2018-02-07 JP JP2019542437A patent/JP6785384B2/ja active Active
- 2018-02-07 EP EP18750794.2A patent/EP3580208B1/fr active Active
- 2018-02-07 PL PL18750794T patent/PL3580208T3/pl unknown
- 2018-02-07 MA MA47469A patent/MA47469B1/fr unknown
- 2018-02-07 RU RU2019124878A patent/RU2733384C1/ru active
- 2018-02-07 ES ES18750794T patent/ES2899665T3/es active Active
- 2018-02-07 SG SG11201906436VA patent/SG11201906436VA/en unknown
- 2018-02-07 TW TW110116961A patent/TWI782525B/zh active
- 2018-02-07 PE PE2019001462A patent/PE20191477A1/es unknown
- 2018-02-07 HU HUE18750794A patent/HUE056218T2/hu unknown
- 2018-02-07 TW TW109107089A patent/TWI772759B/zh active
- 2018-02-07 CN CN201880006571.2A patent/CN110191882B/zh active Active
- 2018-02-07 TW TW107104338A patent/TWI694070B/zh active
- 2018-02-07 US US16/477,575 patent/US10981917B2/en active Active
- 2018-02-07 PT PT187507942T patent/PT3580208T/pt unknown
- 2018-02-07 WO PCT/KR2018/001625 patent/WO2018147626A1/fr unknown
-
2019
- 2019-07-08 SA SA519402180A patent/SA519402180B1/ar unknown
- 2019-07-17 EC ECSENADI201951409A patent/ECSP19051409A/es unknown
- 2019-07-18 CL CL2019002019A patent/CL2019002019A1/es unknown
- 2019-07-22 CO CONC2019/0007834A patent/CO2019007834A2/es unknown
- 2019-07-24 DO DO2019000193A patent/DOP2019000193A/es unknown
- 2019-08-06 PH PH12019501811A patent/PH12019501811A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |